Form D · Pharmaceuticals
Immune Response BioPharma, Inc.
New York, NY · CIK 0001524679
Offering snapshot reported Aug 14, 2012 · SEC filing
- Reported sold
- Yet to sell Offering amount: $1B
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $100 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 14, 2012 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Aug 2, 2011 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Aug 2, 2011 | Amendment | Yet to sell | No comparison | 0 | SEC filing |
| Jul 1, 2011 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire
- Exemptions
- 04, 05, 04.1, 06, 04.2, 46, 04.3
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-182702
Source: Form D, filed Aug 14, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Robert Buswell | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
244 5 Th Avenue Suite 1727
New York, NY, 10001
New York, NY, 10001